Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions (3TR)

Framework: Horizon 2020 — Societal Challenges
Programme: Health, demographic change and wellbeing
Theme: Public-private partnerships
Destination: Innovative Medicines Initiative 2
Action type: Research and Innovation actions
Partnership: IMI2 (Art-187)
Countries involved: Italy,Germany,Germany,Germany,Germany,Germany,Ireland,Italy,Italy,Italy,Italy,Italy,Germany,Spain,Spain,Spain,Italy,Germany,Spain,Spain,Spain,Spain,Italy,Germany,Switzerland,Belgium,Sweden,Switzerland,Norway,Belgium,Belgium,Belgium,Poland,Sweden,Sweden,Switzerland,Belgium,Croatia,France,France,France,France,Netherlands,Netherlands,United States,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,United Kingdom,Denmark,Portugal
Call: Targeted immune intervention for the management of non-response and relapse (H2020-JTI-IMI2-2018-14-two-stage, 2018)
Start date: 2019-09-01
End date: 2026-08-31
Duration (months): 84.0
Total project cost (EUR): 87721177.75
EU funding (EUR): 40273191.5
Participants: 90
Project status: SIGNED

3TR is a transdisciplinary consortium made of experts in all areas of medicine, basic sciences and bioinformatics from academic institutions, SMEs, and 8 major pharmaceutical companies, teamed to study a fundamental issue in medicine: the mechanisms of response and non-response to therapies, the major aim of 3TR, both within single disease entities and across diseases, where molecular stratification may identify shared disease taxonomies. The molecular identification of groups of patients to whom a drug will benefit, will allow focusing on those who are drug orphan. Harmonization of data from existing academy or industry-sponsored studies will identify biomarkers to inform a new collection. Specimens of diseased tissues, blood, stools, and other fluids will be obtained in a de novo observational prospective trial with standard of care medication prior, during and after first or second line of treatment. Because the studies will be at different phases of progression, a carrousel model of work was designed for input and output of data to be continuously analysed, and interpreted, to inform those measurements to be undertaken and allow cross-validation of results. The 3TR team will elucidate the role of the microbiome, genetics and regulatory genomic features in disease progression. The working aims of 3TR are: 1) establish a centralized data management platform; 2) perform comprehensive molecular and clinical characterisation of a prospective patient cohort; 3) establish integrated analysis of all data using advanced bioinformatics/statistical and modelling methods; 4) identify sets of predictive biomarkers of response/non-response to therapies; 5) improve the competitiveness of European industry and support development of novel solutions. 3TR will sustain beyond the project end the samples and its knowledge base. 3TR will challenge and revolutionize the conventional single-disease based approach with important implications in future disease treatment.

Keywords: autoimmunity,inflammation,disease trajectories,stratification,predictive modeling,knowledge base and sample sustainability,single cell data,integrative genomics,agent based modeling,allergy